Unknown

Dataset Information

0

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.


ABSTRACT: Successful adoptive T-cell immunotherapy of solid tumors will require improved expansion and cytotoxicity of tumor-directed T cells within tumors. Providing recombinant or transgenic cytokines may produce the desired benefits but is associated with significant toxicities, constraining clinical use. To circumvent this limitation, we constructed a constitutively signaling cytokine receptor, C7R, which potently triggers the IL7 signaling axis but is unresponsive to extracellular cytokine. This strategy augments modified T-cell function following antigen exposure, but avoids stimulating bystander lymphocytes. Coexpressing the C7R with a tumor-directed chimeric antigen receptor (CAR) increased T-cell proliferation, survival, and antitumor activity during repeated exposure to tumor cells, without T-cell dysfunction or autonomous T-cell growth. Furthermore, C7R-coexpressing CAR T cells were active against metastatic neuroblastoma and orthotopic glioblastoma xenograft models even at cell doses that had been ineffective without C7R support. C7R may thus be able to enhance antigen-specific T-cell therapies against cancer.Significance: The constitutively signaling C7R system developed here delivers potent IL7 stimulation to CAR T cells, increasing their persistence and antitumor activity against multiple preclinical tumor models, supporting its clinical development. Cancer Discov; 7(11); 1238-47. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1201.

SUBMITTER: Shum T 

PROVIDER: S-EPMC5669830 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7226757 | BioStudies
2015-01-01 | S-EPMC4537826 | BioStudies
2019-01-01 | S-EPMC6428219 | BioStudies
1000-01-01 | S-EPMC4395796 | BioStudies
2019-01-01 | S-EPMC6687561 | BioStudies
1000-01-01 | S-EPMC4705591 | BioStudies
2018-01-01 | S-EPMC7590161 | BioStudies
2017-01-01 | S-EPMC5601024 | BioStudies
2021-01-01 | S-EPMC7680719 | BioStudies
2019-01-01 | S-EPMC6645919 | BioStudies